Physician profile
Cesar A Rivera
NPI 1386749620
$1,568.20
in general payments reported to CMS, 2019-2025
16 companies · $252 in 2025
The $252 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2021: $112 · 2022: $241 · 2023: $373 · 2024: $354 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $409.39 | 2021-2024 | Farxiga, Lokelma |
| Lilly USA, LLC | $270.37 | 2023-2025 | Mounjaro, Zepbound |
| Fresenius USA Marketing, INC. | $137.59 | 2019 | |
| Mallinckrodt Hospital Products INC. | $136.68 | 2021-2023 | Acthar |
| Mallinckrodt Enterprises LLC | $99.00 | 2019 | |
| Becton, Dickinson and Company | $94.59 | 2025 | Glidepath |
| Novartis Pharmaceuticals Corporation | $93.37 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.35 | 2024 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $53.56 | 2023-2024 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $45.10 | 2024 | Benlysta |
| Travere Therapeutics, INC. | $33.16 | 2023 | |
| Ani Pharmaceuticals, INC. | $29.84 | 2024 | Purified Cortrophin Gel |
| Genzyme Corporation | $28.26 | 2023 | |
| Medtronic, INC. | $23.79 | 2022 | |
| Pbg Puerto Rico LLC | $19.62 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Puerto Rico INC. | $16.53 | 2023 | Kerendia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.